MX2009006447A - Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. - Google Patents
Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato.Info
- Publication number
- MX2009006447A MX2009006447A MX2009006447A MX2009006447A MX2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A MX 2009006447 A MX2009006447 A MX 2009006447A
- Authority
- MX
- Mexico
- Prior art keywords
- bisphosphonate
- sustained release
- aqueous suspension
- pharmaceutical composition
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan composiciones farmacéuticas para liberación sostenida a largo plazo de fármacos de bisfisfonato. En una modalidad, la composición incluye una suspensión acuosa de un sólido que incluye una sal de un fármaco de bisfosfonato y una sal de oxoácido de fósforo pentavalente. Las composiciones pueden ser utilizadas para tratar una variedad de enfermedades óseas, incluyendo osteoporosis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87680006P | 2006-12-21 | 2006-12-21 | |
US11/768,181 US8974801B2 (en) | 2006-12-21 | 2007-06-25 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
PCT/US2007/025569 WO2008085281A1 (en) | 2006-12-21 | 2007-12-13 | Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009006447A true MX2009006447A (es) | 2009-07-27 |
Family
ID=39543732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009006447A MX2009006447A (es) | 2006-12-21 | 2007-12-13 | Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. |
Country Status (14)
Country | Link |
---|---|
US (3) | US8974801B2 (es) |
EP (2) | EP2548441B1 (es) |
JP (1) | JP5492564B2 (es) |
CN (1) | CN101616591B (es) |
BR (1) | BRPI0720605A2 (es) |
CA (1) | CA2673058C (es) |
DK (2) | DK2548441T3 (es) |
ES (2) | ES2396733T3 (es) |
MX (1) | MX2009006447A (es) |
PL (2) | PL2548441T3 (es) |
PT (2) | PT2548441E (es) |
RU (1) | RU2453316C2 (es) |
SI (1) | SI2120585T1 (es) |
WO (1) | WO2008085281A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2459176T1 (en) | 2009-07-31 | 2018-01-31 | Gruenenthal Gmbh | Crystallization process and bioavailability |
US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
CA2784533C (en) | 2009-12-18 | 2016-02-09 | Howmedica Osteonics Corp. | Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same |
CN102453050B (zh) * | 2010-11-03 | 2015-01-07 | 成都云克药业有限责任公司 | 一种二膦酸化合物及其制备方法 |
ES2714701T3 (es) | 2010-11-10 | 2019-05-29 | Stryker European Holdings I Llc | Proceso para la preparación de una espuma ósea polimérica |
US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
DK2852600T3 (da) * | 2012-05-20 | 2022-01-17 | Univ Bar Ilan | Bisfosfonat-vinylmonomerer og -polymerer og brug heraf |
US9492268B2 (en) | 2012-11-13 | 2016-11-15 | The Secant Group, Llc | Tapered tubular implant formed from woven fabric |
WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
CN108815117A (zh) * | 2018-08-23 | 2018-11-16 | 宁波蒙曼生物科技有限公司 | 一种镇痛药物组合物及其制备方法 |
CN109930209B (zh) * | 2019-03-07 | 2022-02-15 | 华南理工大学 | 一种具高结晶度及长径比双膦酸盐晶体及其制备方法 |
CN112707934A (zh) * | 2020-12-30 | 2021-04-27 | 华南理工大学 | 一种阿仑膦酸钙配合物及其制备方法 |
CN114349786B (zh) * | 2021-12-28 | 2023-07-11 | 中国科学院上海硅酸盐研究所 | 阿仑膦酸钙超长纳米线及其制备方法和应用 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356887A (en) | 1990-01-31 | 1994-10-18 | Merck & Co., Inc. | Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
WO1995008304A1 (en) * | 1993-09-21 | 1995-03-30 | The Penn State Research Foundation | Bone substitute composition comprising hydroxyapatite and a method of production therefor |
US5462932A (en) | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
DE69828635T2 (de) | 1997-09-19 | 2005-06-16 | Shire Laboratories, Inc. | Feste lösungskügelchen |
SE9703691D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
JP2002519305A (ja) | 1998-06-24 | 2002-07-02 | メルク エンド カムパニー インコーポレーテッド | 骨吸収阻害用の組成物および方法 |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6677320B2 (en) | 2000-01-20 | 2004-01-13 | Hoffmann-La Roches Inc. | Parenteral bisphosphonate composition with improved local tolerance |
DK1284754T3 (da) * | 2000-05-05 | 2006-05-01 | Hoffmann La Roche | Gel-lignende farmaceutisk præparat som omfatter biphosphonsyrer eller salte deraf til subkutan administration |
US6350471B1 (en) | 2000-05-31 | 2002-02-26 | Pharma Pass Llc | Tablet comprising a delayed release coating |
US6476006B2 (en) | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
JP4161031B2 (ja) | 2000-10-31 | 2008-10-08 | 独立行政法人産業技術総合研究所 | 亜鉛含有リン酸カルシウム微粒子含有懸濁液または粒子溶媒混合系及び亜鉛欠乏症治療剤 |
GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
US6558702B2 (en) | 2001-04-13 | 2003-05-06 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
FR2836681B1 (fr) | 2002-03-04 | 2004-06-18 | Centre Nat Rech Scient | Compose phosphocalcique modifie, composition injectable le contenant |
US7488496B2 (en) * | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
MXPA06001428A (es) | 2003-08-06 | 2006-05-15 | Rhodia | Metodo para promover el crecimiento del hueso. |
US7420000B2 (en) | 2003-09-10 | 2008-09-02 | University Of Southern California | Amino phosphonate and amino bis-phosphonate derivatives |
US20050261250A1 (en) | 2004-05-19 | 2005-11-24 | Merck & Co., Inc., | Compositions and methods for inhibiting bone resorption |
US8071574B2 (en) * | 2005-02-22 | 2011-12-06 | John Dennis Bobyn | Implant improving local bone formation |
-
2007
- 2007-06-25 US US11/768,181 patent/US8974801B2/en active Active
- 2007-12-13 PL PL12186963T patent/PL2548441T3/pl unknown
- 2007-12-13 ES ES07862893T patent/ES2396733T3/es active Active
- 2007-12-13 DK DK12186963.0T patent/DK2548441T3/en active
- 2007-12-13 PL PL07862893T patent/PL2120585T3/pl unknown
- 2007-12-13 EP EP12186963.0A patent/EP2548441B1/en active Active
- 2007-12-13 MX MX2009006447A patent/MX2009006447A/es active IP Right Grant
- 2007-12-13 WO PCT/US2007/025569 patent/WO2008085281A1/en active Application Filing
- 2007-12-13 SI SI200731112T patent/SI2120585T1/sl unknown
- 2007-12-13 CN CN200780047021.7A patent/CN101616591B/zh active Active
- 2007-12-13 DK DK07862893.0T patent/DK2120585T3/da active
- 2007-12-13 PT PT121869630T patent/PT2548441E/pt unknown
- 2007-12-13 ES ES12186963.0T patent/ES2524690T3/es active Active
- 2007-12-13 EP EP07862893A patent/EP2120585B1/en active Active
- 2007-12-13 RU RU2009128023/15A patent/RU2453316C2/ru not_active IP Right Cessation
- 2007-12-13 CA CA2673058A patent/CA2673058C/en active Active
- 2007-12-13 BR BRPI0720605-4A2A patent/BRPI0720605A2/pt not_active IP Right Cessation
- 2007-12-13 JP JP2009542815A patent/JP5492564B2/ja active Active
- 2007-12-13 PT PT78628930T patent/PT2120585E/pt unknown
-
2015
- 2015-02-13 US US14/622,749 patent/US20150157650A1/en not_active Abandoned
- 2015-02-13 US US14/622,746 patent/US20150157649A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2120585A1 (en) | 2009-11-25 |
EP2120585A4 (en) | 2011-11-23 |
EP2120585B1 (en) | 2012-10-03 |
ES2524690T3 (es) | 2014-12-11 |
PT2548441E (pt) | 2014-11-27 |
PL2548441T3 (pl) | 2015-02-27 |
DK2120585T3 (da) | 2013-01-21 |
EP2548441B1 (en) | 2014-08-27 |
ES2396733T3 (es) | 2013-02-25 |
PT2120585E (pt) | 2013-01-15 |
US20150157649A1 (en) | 2015-06-11 |
CA2673058C (en) | 2015-11-24 |
CA2673058A1 (en) | 2008-07-17 |
CN101616591A (zh) | 2009-12-30 |
US20150157650A1 (en) | 2015-06-11 |
EP2548441A1 (en) | 2013-01-23 |
DK2548441T3 (en) | 2014-12-08 |
JP2010513483A (ja) | 2010-04-30 |
BRPI0720605A2 (pt) | 2014-04-08 |
PL2120585T3 (pl) | 2013-03-29 |
RU2009128023A (ru) | 2011-01-27 |
US8974801B2 (en) | 2015-03-10 |
JP5492564B2 (ja) | 2014-05-14 |
SI2120585T1 (sl) | 2013-05-31 |
CN101616591B (zh) | 2014-06-18 |
US20080153784A1 (en) | 2008-06-26 |
RU2453316C2 (ru) | 2012-06-20 |
WO2008085281A1 (en) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006447A (es) | Composicion farmaceutica de liberacion sostenida a largo plazo que contiene suspension acuosa de bisfosfonato. | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
BRPI0820308A8 (pt) | composições farmacêuticas | |
MX2023008180A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
BRPI0710508B8 (pt) | composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído | |
CR20110110A (es) | Composicion farmaceutica | |
BRPI0516830A (pt) | composições de droga de liberação sustentada convenientemente implantáveis | |
IN2012DN01216A (es) | ||
WO2008105773A3 (en) | System for targeted delivery of therapeutic agents | |
IL201581A (en) | Pharmaceutical formulations containing fatty acid derivatives and ion-forming substances | |
TN2012000392A1 (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
MX2009004439A (es) | Composicion de ibuprofeno. | |
BRPI0807285A2 (pt) | "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto" | |
MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
MX2011011829A (es) | Composicion para suministro sostenido de farmaco que comprende un aglutinante geopolimerico. | |
ECSP066860A (es) | Formulaciones de matriz oral que comprenden licarbazepina | |
UA83900C2 (en) | Amorphous forms of risedronate monosodium | |
WO2008070141A3 (en) | Compositions for delivery of therapeutic agents | |
MX371297B (es) | Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz. | |
WO2010033981A3 (en) | 5-azaindole bisphosphonates | |
ZA200904563B (en) | Transdermal Therapeutic system for administering water-soluble active ingredients | |
CY1113702T1 (el) | Φαρμακευτικη συνθεση μακροχρονιας κατακρατημενης αποδεσμευσης περιεχοντας υδατικο εναιωρημα διφωσφονικου | |
IN2014CN02343A (en) | Oral formulations containing hyaluronic acid for sustained drug release | |
TW200833325A (en) | Pharmaceutical composition comprising ascorbic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |